Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414012 | 1.00 | NR4A2 (0.53) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL30412953 | 0.84 | NR4A2 (0.57) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL978508 | 0.84 | NR4A2 (0.74) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL30412532 | 0.84 | NR4A2 (0.74) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL978359 | 0.84 | NR4A2 (0.57) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL1437471 | 0.82 | MAOB (0.68) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL4639188 | 0.82 | NR4A2 (0.56) | NR4A2NPC1RAB9ANR4A1NR4A3 | |
| SCHEMBL30413678 | 0.82 | MRGPRX4 (0.59) | NR4A2MAOBMAOAMRGPRX4SMPD1 | |
| SCHEMBL980871 | 0.82 | MRGPRX4 (0.59) | NR4A2MAOBMAOAMRGPRX4SMPD1 | |
| SCHEMBL30411777 | 0.80 | NR1H4 (0.64) | NR4A2NPC1RAB9ANR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9422253-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2016-08-23 | — | — | US | disclosed |
| EP-3002280-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2229371-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2014-06-05 | — | — | US | disclosed |
| CN-103705519-A | Cyclic triazo and diazo sodium channel blockers | UNIV GREENWICH | 2014-04-09 | — | — | CN | disclosed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2229371-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009090431-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | NR4A2 833/4885NPC1 447/4885RAB9A 2647/4885 |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | CACNA1E, SCN2B, SCN3A | NR4A2 899/4885NPC1 1211/4885RAB9A 359/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | NR4A2 842/4885NPC1 529/4885RAB9A 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.